Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...
Bio-Techne is set to announce its third-quarter earnings next month, and Wall Street expects the company’s EPS to decrease by ...
Bio-Techne Corporation (NasdaqGS:TECH) is rolling out a new brand architecture centered on three portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The updated structure ...
RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Bio-Techne Corporation TECH is set to release second-quarter fiscal 2026 results on Feb. 4, before the opening bell. The life science and diagnostic product maker posted adjusted earnings per share ...
In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...
Bio-Techne Corporation TECH recently announced new advancements in its spatial biology portfolio for the RNAscope ISH technology and the Lunaphore COMET. Research highlights the potential role of ...
Bio-Techne is a leading provider of specialized reagents, analytical instruments, and diagnostic solutions for the life sciences and clinical diagnostics sectors. The company leverages a diverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results